

Research Article

Prognostic determinants of anterior large vessel occlusion in acute stroke in elderly patients.

Takashi Mitsuhashi MD, Ph D.^a, Kohsuke Teranishi MD, Ph D.,^b Joji Tokugawa MD, Ph D.^a, Takumi Mitsuhashi MD., Ph D.^a, Makoto Hishii MD, Ph D.^a, Hidenori Oishi MD, Ph D.^{b,c}

^a Department of Neurosurgery/Juntendo University/Nerima Hospital, Tokyo, Japan

^b Department of Neurosurgery/ Juntendo University/Tokyo, Japan

^c Department of Neuroendovascular Therapy/ Juntendo University/Tokyo, Japan

Short Title: Prognostic Factors in Elderly Patients Undergoing Mechanical Thrombectomy

Corresponding Author:

Takashi Mitsuhashi

Department of Neurosurgery, Juntendo University Nerima Hospital

3-1-10 Takanodai, Nerima-ku, Tokyo, Japan

Tel: +81-3-5923-3111

E-mail: ta-kashi@wa2.so-net.ne.jp

Number of Tables: 4.

Number of Figures: none.

Word count: 3898

Keywords: Mechanical thrombectomy, Large vessel occlusion, elderly, prognosis

1 **Abstract**

2 **Introduction.**- Mechanical thrombectomy(MT) has been shown to be safety and
3 effectiveness for acute anterior circulation large vessel occlusion(LVO)of all ages, and
4 together with intravenous thrombolysis has become an standard treatment for acute stroke.
5 In an aging world, the effectiveness of MT for the elderly has not been fully demonstrated.
6 We investigated factors associated with prognosis in elderly patients undergoing MT in
7 Japanese practice, where the elderly are defined as those aged 80 years or older, in the
8 context of an ageing population.

9 **Method.**- MT was performed in 59 cases of LVO of the anterior circulation. Primary outcome
10 evaluated functional outcome at three months. Parametric and/or non-parametric test and a
11 binomial logistic regression model was performed to identify prognosis factors in elderly
12 patients.

13 **Results.**- Overall, Of the 59 patients, 47.5% (28/59) achieved an mRS ≤ 3 at 3 months.
14 Mortality rate was 20.3% (12/59). Younger age($P=0.032$), lower NIHSS on
15 admission($P=0.00005$), lower level of NT-proBNP on admission($P=0.041$), lower level of D-
16 dimer on admission($P=0.01$), First Pass Effect (FPE) ($P=0.024$) and good
17 recanalization($P=0.0025$) were associated with favorable clinical outcome. In the binomial
18 logistic regression model, only lower NIHSS on admission was significantly associated with
19 good clinical outcome.

20 **Conclusions.**- In the present study, not only were younger age, lower NIHSS on admission
21 and FPE already reported as prognostic factors for MT for LVO in the elderly, but also,
22 although not previously reported, lower levels of NT-proBNP on admission and lower level of
23 D-dimer on admission were considered as possible prognostic factors.

24

25 **Introduction**

26 Several randomised controlled trials of mechanical thrombectomy (MT) for the treatment of
27 acute anterior circulation large vessel occlusion (LVO) have demonstrated efficacy and safety
28 in all age groups. [1]

29 MT has become one of the standard treatments for acute ischemic stroke caused by LVO,
30 along with intravenous thrombolysis. Some guidelines recommended considering MT for
31 occlusion of the M1 segment of the middle cerebral artery or internal carotid artery. [2,3] As
32 Hendrix et al. also pointed out, although the guideline proved to be a class 1 recommendation
33 for MT in patients over 80 years of age, several RCTs have excluded patients over 80 or 85
34 years of age.[4]

35 On the other hand, it is recognized that life expectancy has increased worldwide in recent
36 years and that the risk of developing ischemic stroke is thought to increase as the number of
37 older people increases and as they get older. Some previous studies have shown that people
38 over 80 years of age have the highest incidence of acute ischemic stroke. [5]

39 However, the evidence for MT in elderly patients with LVO is scarce and not explicitly stated
40 in the guidelines. Furthermore, Alawieh et al. point out that many of the previous conclusions
41 regarding the efficacy and safety of MT in the elderly were based on single-arm, single-
42 institute studies, resulting in significant heterogeneity among studies and a lack of comparison
43 with optimal medical management. [6]

44 Previous studies on MT for LVO have highlighted advanced age as a strong predictor of
45 unfavorable outcome after MT. [7,8]

46 Japan has the highest ageing rate in the world, and other developed countries are also
47 expected to become ageing societies.

48 The safety and efficacy of MT for LVO have been reported in octogenarians, nonagenarians,
49 and elderly patients with LVO, including prognosis-related factors.

50 Factors contributing to outcome include successful reperfusion, first pass effect (FPE), low
51 NIHSS score on admission, initial ASPECTS, time from onset to groin puncture, time from
52 groin puncture to recanalization, pre-existing functional deficits, and age over 80 years.
53 [6,9,10,11,12,13]

54 Although, the HERMES meta-analysis showed that MT had beneficial effects in patients aged
55 80 years or older patients, the proportional of cases over 80 years of age was low. [1]
56 Therefore, the current guidelines for the United States provide class 1 recommendation for
57 MT in patients aged 80 years or older. [14]

58 Therefore, Zaidat et al. dichotomized patient age based on previous studies, using 80 years as
59 the cut-off point and defining elderly patients as those aged 80 years or older. In the TRACK
60 registry, age ≥ 80 years was reported to be a prognostic factor and that the rate of patients with
61 an mRS score 0 to 2 at 90 days decreased slightly with age.[15]

62 In addition, Meyer et al. pointed out that no substantial therapy recommendation for patients
63 aged 90+ was derived from the recent landmark thrombectomy trials. [16]

64 In the present study, we defined "elderly" as those over 80 years of age because, as mentioned
65 above, many studies, including previous guidelines, often set the age at which a person is
66 considered elderly at 80 years. Furthermore, since the average life expectancy of Japanese
67 men is in the early 80s and that of women in the mid 80s, we defined those aged 80 and over
68 as elderly.

69 Since many elderly patients have undergone MT for LVO in our medium-sized hospital in
70 Japan, which has an aging population, we investigated the results of MT for LVO in elderly
71 patients and reviewed the prognostic factors. To identify factors associated with favorable
72 outcome in patients who have underwent MT for LVO.

73 **Materials and Methods**

74 **Patient selection**

75 Consecutive 141 patients who underwent MT for anterior circulation LVO at our hospital
76 between October 2015 and October 2021 were retrospectively reviewed. In this retrospective
77 single-center study, the protocol was approved by the ethics committee of Juntendo
78 University Nerima Hospital.

79 The inclusion criteria of the present study were as follows; (1) acute ischemic stroke due to
80 LVO within the anterior circulation, including the internal carotid artery (ICA) or middle
81 cerebral artery (MCA), with or without additional intravenous thrombolysis; (2) age at onset
82 is 80 years or older; (3) known admission National Institute of Health Stroke Scale

83 (NIHSS), Alberta Stroke Program Early CT Score (ASPECTS), and Diffusion-weighted
84 imaging ASPECTS (DWI-ASPECTS) for patients who are eligible for magnetic resonance
85 imaging; (4) known values of the premorbid modified Rankin Scale (mRS) and mRS at 90
86 days after stroke.

87 Data were collected on age at admission, sex, time of onset or last known well time, time of
88 arrival at our institute, NIHSS at admission, blood collection data at admission (N-Terminal
89 Pro-Brain Natriuretic Peptide (NT-proBNP) (pg/ml), D-dimer ($\mu\text{g/ml}$), Glycated hemoglobin
90 (HbA1c) (%)), time of recanalization, number of attempts, and angiographic recanalization
91 status as modified thrombolysis in cerebral infarction (mTICI).

92 In this study we defined a clinical outcome mRS 0-3 as favorable clinical outcome, for the
93 following reasons.

94 The mRS is a non-linear scale, a measure of Activity of Daily Life that focuses primarily on
95 mobility, and dichotomization of outcomes has been used in research studies. Many previous
96 studies, including HERMES, have treated mRS0-2 as a good clinical outcome. [1] However,
97 Wilson et al. pointed out that the lower inter-rater reliability in classifying patients as mRS2
98 and 3 or by the existence of subgroups within the mRS3 group. [17] In Addition, Rangraju et
99 al. described that the patients who achieved mRS3 were more similar to mRS2 than mRS4
100 patients in terms of on functional disability and quality of life. [18]

101 The majority of patients underwent MT under local anesthesia with the use of a stent-retriever
102 and/or an aspiration catheter.

103 **Study End Points**

104 The primary neurological end point of this study was the rate of favourable clinical outcome
105 defined as mRS ≤ 3 at 90-day follow up, adjusted for patient age.

106 **Statistical analysis**

107 Variables were compared between two groups: mRS 0-3; favourable clinical outcome and 4-
108 6; unfavourable clinical outcome, using either the t-test or the Mann-Whitney-U test (M-W
109 test), as appropriate, to compared variables between groups. We also developed and analysed
110 a binomial logistic regression model to predict favourable or unfavourable clinical outcomes.

111 P-values of <0.05 were considered statistically significant. IBM SPSS version 25 (Chicago,
112 IL, USA) was used for data analysis.

113 **Results**

114 **Patient characteristics**

115 Fifty-nine elderly patients aged over 80 years met the inclusion criteria and were treated
116 between October 2015 and October 2021.

117 The median age was 85 years (IQR 83-87) and 61.02% (27/59) were female. The median pre-
118 morbid mRS was 0 (IQR0-1), but the mean value was 0.559.

119 Patients were admitted to hospital with a median NIHSS score of 24 (IQR 18-27), a median
120 baseline ASPECTS score of 9 (IQR 7-9), and a median baseline DWI-ASPECTS score of 7
121 (IQR 6-8). Six patients were unable to undergo MRI due to metallic implants in their body.

122 The most common cardiovascular risk factors (Table 1.) were hypertension (83.1%, 49/59),
123 diabetes mellitus (20%, 12/59), hyper lipidemia (13.6%, 8/59) and arterial fibrillation
124 (56%,33/59). There is no statistically significant difference in cardiovascular risk factors
125 between the favourable and unfavourable clinical outcome groups by t-test and M-W test
126 ($p=0.7802$ and $p=0.7728$). The most common site of occlusion (Table 2.) was the middle
127 cerebral artery (MCA), particularly the M1 segment (28.9%,17/59): other site in the anterior
128 circulation included the internal carotid artery (ICA) (22%, 13/59), the MCA M2 segment
129 (18.6%,11/59), the cervical segment of ICA (6.8%, 4/59), and the intracranial segment of ICA
130 (5%, 3/59). There is no statistically significant difference in the site of occlusion between the
131 favourable and unfavourable clinical outcome groups by t-test and M-W test ($p=0.8129$ and
132 $p=0.7481$).

133 More than half patients (61.02%,36/59) underwent intravenous thrombolysis prior to MT.

134 Base-line characteristics at admission were compared between favourable clinical outcome
135 (mRS ≤ 3) and unfavourable clinical outcome (mRS >3) at 90days after admission. (table 3.)

136 In terms of age, the median age in the favourable clinical outcome group was 84 years (IQR
137 82.75-86), while the median age in the unfavourable clinical outcome group was 86 years
138 (IQR 83-90), a statistically significant difference found by t-test ($p=0.0319$) (Table.3). In
139 terms of time from onset to arrival, the median time in the favourable clinical outcome group

140 was 52 minutes (IQR 38.75-165.75) and the median time in the unfavourable clinical outcome
141 group was 57 minutes (IQR 39.5-157), with no statistically significant difference by t-test and
142 M-W test ($p=0.186$ and $p=0.9214$) (Table.3). The median NIHSS score on admission was 20
143 (IQR 16-24.25) in the favourable clinical outcome group and 26 (IQR 22.5-30) in the
144 unfavourable clinical outcome group, a statistically significant difference was found by both t-
145 test and M-W test ($p=0.0005$ and $p=0.0008$) (Table.3). For ASPECTS and DWI-ASPECTS on
146 admission, the median ASPECTS in the favourable clinical outcome group was 9 (IQR 7-
147 9.25) and the median DWI-ASPECTS was 7.5 (IQR 6-9), whereas in the unfavourable
148 clinical outcome group the median ASPECTS was 9 (IQR 7-9) and the median DWI-
149 ASPECTS was 8 (IQR 6-8), and there was no statistically significant difference in either
150 group by t-test and M-W test ($p=0.0962$ and $p=0.2867$, and $p=0.3511$ and $p=0.587$) (Table.3).
151 For the NT-proBNP level (pg/ml) on admission, the median for the favourable clinical
152 outcome group was 636.65 (pg/ml) (IQR 314.2-913), while the median for the unfavourable
153 clinical outcome group was 1195.5 (pg/ml) (IQR 746.6-1814), a statistically significant
154 difference was found by M-W test ($p=0.0403$) (Table.3). For admission D-dimer level (μg
155 /ml), the median for the favourable clinical outcome group was 1.25 ($\mu\text{g/ml}$) (IQR 1.2-4.05),
156 while the median for the unfavourable clinical outcome group was 2 ($\mu\text{g/ml}$) (IQR 0.875-1.8),
157 a statistically significant difference was found by M-W test ($p=0.0104$) (Table.3). On the
158 other hand, the median HbA1c level (%) on admission was 5.9 (%) (IQR 5.5-6) in the
159 favourable clinical outcome group and 6 (%) (IQR 5.625-6.475) in the unfavourable clinical
160 outcome group, which was not statistically significant by t-test and M-W test ($p=0.2431$ and
161 $p=0.211$) (Table.3).

162 In binomial logistic regression analysis with further investigation, only a lower NIHSS score
163 on admission was significantly correlated with a good clinical outcome ($p=0.010$).

164 Although no significant correlations were found, there was a trend for favourable clinical
165 outcome to correlate with younger age; NT-proBNP showed a slight tendency to correlate
166 with favourable outcome (Table.4).

167 **Procedural and functional outcomes**

168 These favorable clinical outcomes ($\text{mRS} \leq 3$) were observed in 47.5% (28/59) of patients at
169 90-days after admission. Post-interventional in-hospital mortality was 20.3% (12/59).

170 Successful angiographic recanalization (mTICI \geq 2b) was achieved in 74.6% (44/59) of
171 patients. In contrast, unsuccessful recanalization (mTICI 0) occurred in four cases (6.8%).

172 The percentage of good recanalization with mTICI 2b or better was 92.9% (26/28) in the
173 favourable clinical outcome group and 58.1% (18/31) in the unfavourable clinical outcome
174 group, a statistically significant differences was found in both t-test and M-W test ($p=0.0018$
175 and $p=0.0025$) (Table.3).

176 For the number of attempts, the median for the favourable clinical outcome group was 1(IQR
177 1-2) and the median for the unfavourable clinical outcome group was 2(IQR 1-2), a
178 statistically significant differences was found in both t-test and M-W test ($p=0.0225$ and
179 $p=0.0244$) (Table.3). For arrival to recanalization time (min), the median for the favourable
180 clinical outcome group was 145 (min) (IQR 110.75-178.25), and the median for the
181 unfavourable clinical outcome group was 140 (min) (IQR 117-177), which was not
182 statistically significant by t-test and M-W test ($p=0.4178$ and $p=0.8064$) (Table.3). For
183 puncture to recanalization time (min), or procedure time, the median for the favourable
184 clinical outcome group was 41 (min) (IQR 21.5-57.25) , and the median for the unfavourable
185 clinical outcome group was 53 (min) (IQR 36-72) , which was not a statistically significant
186 difference by t-test and M-W test ($p=0.2049$ and $p=0.054$) (Table.3).

187 Binomial logistic regression analysis showed no significant correlations, but there was a trend
188 for cases with TICI \geq 2b and fewer attempts to correlate with favourable clinical outcomes
189 (Table.4).

190 **Discussion/Conclusion**

191 In this study, in patients over 80 years of age undergoing MT for LVO, the factors associated
192 with a favourable clinical outcome on t-test and M-W test were younger age, lower NIHSS
193 score on admission, lower level of NT-proBNP on admission, lower level of D-dimer on
194 admission, FPE (first pass effect) and good recanalisation, However, binomial logistic
195 regression analysis showed that only a lower NIHSS score on admission was significantly
196 associated with a favourable clinical outcome. For the other factors, only a trend was
197 associated with a favourable clinical outcome.

198 Based on the hypothesis that many of the younger patients included in many reports of MT
199 outcomes in LVO, including HERMES, had a pre-stroke mRS of 0 [1],

200 If moving from an mRS of 0 to 2 is considered a favourable clinical outcome, the mean pre-
201 stroke mRS of our study group, consisting of patients over 80 years of age, was 0.559, which
202 is consistent with moving from an mRS of 0 to 3, and we defined an mRS of 0-3 as a
203 favourable clinical outcome.

204 **Age**

205 In this study, although there were statistically significant differences in t-test, binomial
206 logistic regression analysis showed no significant differences, although it is clear that the
207 older the patient, the unfavourable clinical outcome. Similar findings have been reported
208 previously. [19,20,21] As previously noted, pre-existing physical and/or cognitive disability
209 and the high incidence of complications during hospitalization were thought to limit the
210 potential for post-stroke rehabilitation with increasing age. [16]

211 In this study of elderly patients with mRS6, deaths from infectious complications such as
212 aspiration pneumonia were more common, and deaths from malignant oedema or
213 intraparenchymal haemorrhagic infarction due to stroke were very rare. In the background,
214 many elderly patients have complications such as frailty, and it is thought that their sputum
215 expectoration and other functions are also declining, so it is necessary to pay attention to
216 infectious complications, especially aspiration pneumonia.

217 In older patients, atherosclerotic changes in the access route are often significant, and
218 treatment may be discontinued due to access difficulties. If such good recanalization is not
219 achieved, a good clinical outcome is unlikely. [12]

220 **NIHSS score on admission**

221 In this study, the only factors that were found to be significantly associated between lower
222 NIHSS scores on admission and favourable clinical outcomes were found not only in the t-test
223 and M-W test, but also in binomial logistic regression analysis. Similar findings have been
224 reported previously. [12,22]

225 Higher NIHSS scores reflect a more extensive cerebral ischaemic state and may indicate
226 ischaemic symptoms due to more proximal occluded arteries; Arsava et al. have noted the
227 presence of poor collateral circulation [23].

228 **D-dimer**

229 In this study, there was a statistically significant difference between a high level of D-dimer
230 and an unfavorable clinical outcome in M-W test, but not in binomial logistic regression
231 analysis. D-dimer is a degradation product of cross-linked fibrin and a biomarker of the
232 fibrinolytic and coagulation system. [24] Elevated D-dimer levels in acute ischemic stroke
233 have been associated with functional prognosis, acute morbidity, and infarct size.
234 [25,26,27,28]

235 Hisamitsu et al. described that in patients with acute stroke, elevated D-dimer levels may be
236 related to increased activation of the fibrinolytic system in the thrombus of the occluded
237 artery, and the larger the thrombus, the greater the increase. [29] Furthermore, they
238 speculated that a high D-dimer level leads to an unfavourable clinical outcome because the
239 amount of thrombus in the occluded artery is high, making it difficult to achieve a first pass
240 effect (FPE), resulting in distal embolization and prolonged procedure time.

241 **NT-ProBNP**

242 BNP is mainly synthesized cardiomyocytes in response to increased cardiac chamber wall
243 stress. [30] Activation of BNP produces an inactive NT-proBNP(N-terminal pro-brain
244 natriuretic peptide). [31] NT-proBNP has a longer half-life than BNP and results in less
245 fluctuation, but has been reported to be associated with adverse clinical outcomes. [32,33,34]
246 Plasma NT-proBNP levels have been reported to be elevated in patients with heart failure, left
247 ventricular dysfunction, acute coronary syndromes, and cardiogenic stroke.[35,36] In
248 addition, NT-pro BNP is a biological marker of cerebrovascular disease for identifying
249 ischemic stroke subtypes, and predicting the incidence of arterial fibrillation related stroke.
250 [37,38] In this study, almost all patients with elevated plasma NT-proBNP had a cardiogenic
251 embolism. Furthermore, there is increasing evidence that serum levels of NT-proBNP are
252 associated with an increasing risk of adverse clinical outcome in patients after stroke. [33,39]

253 There are no reports on the association between NT-proBNP and prognosis in MT for LVO in
254 the elderly patients. Chronic heart failure has been reported to exacerbate cerebrovascular
255 disease, dementia, and pneumonia and to reduce cardiac activity. [40,41,42]

256 In this study, although there were statistically significant differences in the association of FPE
257 with favourable clinical outcomes in both t-test and M-W tests, there were no significant
258 differences in binomial logistic regression analysis. The results suggesting that cardiac

259 function also contributes to improved prognosis after rehabilitation. Therefore, cardiac
260 function may be an indicator of functional prognosis after MT for LVO.

261 In this study, NT-proBNP levels were elevated well above 150 ng/ml, which is considered a
262 marker for heart failure. However, most patients had no obvious symptoms of heart failure.
263 In a case-cohort study from the REGARDS cohort, the authors confirmed that the association
264 of NT-proBNP with stroke was stronger for cardioembolic stroke. [43]

265 Zhang et al. proposed that three possible mechanisms of NT-pro BNP elevation; ①
266 central blood vessels damage promotes massive release of NT-proBNP from the CNS
267 to the blood, resulting in an absolute increase of NT-proBNP, ② NT-proBNP
268 concentrations derived from the same precursor protein increase simultaneously
269 when cerebral infarction occurs; however, because of their different patterns of
270 metabolism, the activation of the endocrine system controlled by CNS degrade
271 BNP more than NT-proBNP, resulting in a relative increase of NT-proBNP, ③
272 following the deterioration that occurs due to heart failure, organisms begin to mobilize
273 activity factors that collaborate with the rennin-angiotensin-aldosterone system to
274 induce a diastolic state in blood vessels. [44]

275 In this study, the mechanism of NT-proBNP level elevation in LVO is not only one of
276 the above three possibilities, but also the result of a sudden increase in blood pressure to
277 promote spontaneous recanalization of the main artery occlusion, which may have
278 resulted in an excessive cardiac load.

279 The cases with elevated level of NT-proBNP and unfavorable clinical outcome included those
280 who died due to complications such as heart failure or aspiration pneumonia during the course
281 of hospitalization. Some cases were already complicated by aspiration pneumonia at the onset
282 of hospitalization, which may have played a role in the elevated NT-proBNP levels.

283 Many of the cases with elevated level of NTproBNP are consequently older with higher
284 NIHSS, suggesting that more severe and more extensive fast running has occurred since then,
285 and the elevation may be the result of greater sympathetic activation

286 In the present study, the regression analysis failed to produce significant results due to
287 insufficient power of number. Therefore, if n is increased, the regression model may be able to
288 produce results showing that NPproBNP is an independent predictor of prognosis.

289 **FPE**

290 In this study, although there were statistically significant differences in both t-test and M-W
291 test, binomial logistic regression analysis showed no significant differences. Zaidat et al.
292 showed that patients with mTICI 3 had better clinical outcome, lower mortality and fewer
293 procedural adverse events after one pass.[45] Rousiers ED et al. described that FPE is a
294 significant determinant of good clinical outcome in the oldest patients. Similar effects were
295 observed in our results. [18] FPE has been shown to reduce procedure time, ischemic core
296 volume expansion, and the incidence of procedural complications. [46,47] However, our
297 results on puncture to recanalization time showed no correlation with clinical outcome.

298

299 **Limitations**

300 Nevertheless, the present study has some limitations. The study design is retrospective and
301 non-randomized with a small sample size treated at a single institution. We did not compare
302 patients treated with MT with those treated medical treatment including thrombolysis alone.
303 We did not perform serial measurement of NT-proBNP levels and D-dimer levels; therefore,
304 we were unable to examine the association of changes in these levels during after acute stroke
305 phase. In the future, patient data should be accumulated and a large-scale prospective study
306 should be conducted. Although the regression analysis could not produce significant results
307 due to the insufficient power of the number, a certain trend can be observed, so if the number
308 is increased in the future, it may be possible to produce results of an independent prognostic
309 predictor in a regression model.

310

311 **Conclusion**

312 The study found that factors associated with favourable clinical outcomes in patients aged
313 80 years or older undergoing MT for LVO were younger age, lower NIHSS score on
314 admission, lower level of NT-proBNP on admission, lower level of D-dimer on admission,

315 FPE, and better recanalisation, with a strong correlated with lower NIHSS on admission, but a
316 trend was observed for other factors. There are no reports on the correlation between NT-
317 proBNP levels on admission and favourable clinical outcomes in MT for LVO in the elderly,
318 and further verification is needed.

319

320 **Acknowledgments**

321 The medical assistants at Juntendo Nerima Hospital, Miyuki Yanagi and YokoTanaka, are
322 thanked for their cooperation in data collection..

323 **Statement of Ethics**

324 This retrospective single-center study, the protocol was approved by the Ethics Review Board
325 at Juntendo University Nerima Hospital (18-39).

326

327 **Conflict of Interest Statement**

328 The authors have no conflicts of interest to declare.

329 **Funding Sources**

330 This work was supported by JSPS KAKENHI (Grant Numbers 21K18443).

331 **Author Contributions**

332 Takashi Mitsuhashi had full access to all of the data in the study and take responsibility for the
333 integrity of the data and the accuracy of the data analysis. Concept and design: Takashi
334 Mitsuhashi, Kohsuke Teranishi, Joji Tokugawa, Makoto Hishii, and Hidenori Oishi.
335 Acquisition of data: Takashi Mitsuhashi. Drafting of the manuscript: Takashi Mitsuhashi, Joji
336 Tokugawa, and Takumi Mitsuhashi. Critical revision of the manuscript for important
337 intellectual content: Kohsuke Teranishi and Hidenori Oishi. Obtained funding: Takashi
338 Mitsuhashi and Joji Tokugawa.

339 **Data Availability Statement**

340 The data that support the findings of this study are not publicly available due to their
341 containing information that could compromise the privacy of research participants but are
342 available from the corresponding author upon reasonable request.

References

1. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischemic stroke: a meta-analysis of individual patient data from five randomized trials. *Lancet*. 2016;387(10029):1723-1731, [https://doi.org/10.1016/S0140-6736\(16\)00163-X](https://doi.org/10.1016/S0140-6736(16)00163-X).
2. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for health care professional from the American Heart Association/American Stroke Association. *Stroke*. 2019;50:e344-e418, <https://doi.org/10.1161/STR.0000000000000211>.
3. Yamagami H, Hayakawa M, Inoue M, Iihara K, Ogasawara K, Toyoda K, et al. Guidelines for mechanical thrombectomy in Japan, the fourth edition, March 2020: a guideline from the Japan Stroke Society, the Japan Neurosurgical society, and the Japanese Society for Neuroendovascular Therapy. *Neurol Med Chir (Tokyo)*. 2021;61(3):163-92, <https://doi.org/10.2176/nmc.nmc.st.2020-0357>.
4. Hendrix P, Killer-Oberpfalzer M, Broussalis E, Melamed I, Sharma V, Mutzenbach S, et al. Outcome following mechanical thrombectomy for anterior circulation large vessel occlusion stroke in the elderly. *Clin Neuroradiol*. 2022;32(2):369-374, <https://doi.org/10.1007/s00062-021-01063-9>.
5. Writing group members; Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee; Stroke statistics subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. *Circulation*. 2016;133:e38-360, <https://doi.org/10.1161/CIR.0000000000000350>.
6. Alawieh A, Starke R, Chatterjee AR, Turk A, De Leacy R, Rai AT, et al. Outcomes of endovascular thrombectomy in the elderly: a real-world multicenter study. *J Neurointervent Surg*. 2019;11(6):545-553, <http://dx.doi.org/10.1136/neurintsurg-2018-014289>.
7. Duffis EJ, He W, Prestigiacomo CJ, Gandhi CD. Endovascular treatment for acute ischemic stroke in octogenarians compared with younger patients: a meta-analysis. *Int J Stroke*. 2014;9(3):308-12. <https://doi.org/10.1111/ijvs.12098>.
8. Zeevi N, Kuchel GA, Lee NS, Staff I, McCullough LD. Interventional stroke therapies in the elderly: are we helping? *AJNR Am J Neuroradiol*. 2012;33(4):638-42, <https://doi.org/10.3174/ajnr.A2845>.
9. Meyer L, Alexandrou M, Flottmann F, Deb-Chatterji M, Abdullayev N, Maus V, et al. Endovascular treatment of very elderly patients aged ≥ 90 with acute ischemic stroke. *J Am Heart Assoc*. 2020;9(5):e014447, <https://doi.org/10.1161/JAHA.119.014447>

10. Rousiers ED, Lucas L, Richard S, Consoli A, Mazighi M, Labreuche J, et al. Impact of reperfusion for nonagenarians treated by mechanical thrombectomy insights from the ETIS registry. *Stroke*. 2019;50(11):3164-3169, <https://doi.org/10.1161/STROKEAHA.119.026448>.
11. Imahori T, Tanaka K, Arai A, Shiomi R, Fujiwara D, Mori T, et al. Mechanical thrombectomy for acute ischemic stroke patients aged 80 years or older. *J Stroke Cerebrovasc Dis*. 2017; 26(12):2793-2799, <https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.06.060>.
12. Barral M, Lassalle L, Dargazanli C, Mazighi M, Redjem H, Blanc R, et al. Predictors of favorable outcome after mechanical thrombectomy for anterior circulation acute ischemic in octogenarians. *J of Neuroradiol*. 2018;45(4):211-216, <https://doi.org/10.1016/j.neurad.2018.01.055>.
13. Derex L, Haesebaert J, Odier C, Alesefir W, Berthezene Y, Buisson M, et al. Predictors of outcome after mechanical thrombectomy in stroke patients aged 85 years. *Canadian J of Neurol sci*. 2022;49(1):49-54, <https://doi.org/10.1017/cjn.2021.37>.
14. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. *Stroke*. 2019;50(12):e344-418. <https://doi.org/10.1161/STR.0000000000000211>.
15. Zaidat OO, Castonguay AC, Nogueira RG, Haussen DC, English JD, Satti SR, et al. TREVO stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry. *J Neurointerv Surg*. 2018;10(6):516-524, <http://dx.doi.org/10.1136/neurintsurg-2017-013328>.
16. Meyer L, Alexandrou M, Leischner H, Flottmann F, Deb-Chatterji M, Abdullayev N, et al. Mechanical thrombectomy in nonagenarians with acute ischemic stroke. *J Neurointerv Surg*. 2019;11(11):1091-1094, <http://dx.doi.org/10.1136/neurintsurg-2019-014785>.
17. Wilson JTL, Hareendran A, Hendry A, Potter J, Bone I, Muir KW. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. *Stroke*. 2005;36(4):777-781, <https://doi.org/10.1161/01.STR.0000157596.13234.95>.
18. Rangaraju S, Haussen D, Nogueira RG, Nahab F, Frankel M. Comparison of 3-month stroke disability and quality of life across modified Rankin Scale categories. *Intervet Neurol*. 2017;6(1-2):36-41, <https://doi.org/10.1159/000452634>.
19. Hussein HM, Georgiadis AL, Vazquez G, Miley JT, Memon MZ, Mohammad YM, et al. Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study. *AJNR Am J Neuroradiol*. 2010;31(3):454-8, <https://doi.org/10.3174/ajnr.A2006>.
20. Singer OC, Haring HP, Trenkler J, Nolte CH, Bohner G, Reich A, et al. Age dependency of successful recanalization in anterior circulation stroke: the ENDOSTROKE study. *Cerebrovasc*

- Dis. 2013;36(5-6):437-45, <https://doi.org/10.1159/000356213>.
21. Nogueira RG, Liebeskind DS, Sung G, Duckwiler G, Smith WS, MERCI; Multi MERCI writing Committee. Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the mechanical embolus removal in cerebral ischemia (MERCi) and multi MERCI trials. *Stroke*. 2009; 40(12):3777-83, <https://doi.org/10.1161/STROKEAHA.109.561431>.
 22. Kurre W, Aguilar-Perez M, Niehaus L, Fischer S, Schmid E, Bazner H, et al. Predictors of outcome after mechanical thrombectomy for anterior circulation large vessel occlusion in patients aged ≥ 80 years. *Cerebrovasc Dis*. 2013;36(5-6):430-6, <https://doi.org/10.1159/000356186>.
 23. Arsava EM, Vural A, Akpinar E, Gocmen R, Akcalar S, Oguz KK, et al. The detrimental effect of aging on leptomeningeal collaterals in ischemic stroke. *J Stroke Cerebrovasc Dis*. 2014; 23(3):421-6, <https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.03.014>.
 24. Goldenberg NA, Jenkins S, Jack J, Armstrong-Wells J, Fenton LZ, Stence NV, et al. D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic stroke. *J Pediatr*. 2013;162(5):1041-6.e1, <https://doi.org/10.1016/j.jpeds.2012.11.035>.
 25. Dougu N, Takashima S, Sasahara E, Taguchi Y, Toyoda S, Hirai T, et al. Predictors of poor outcome in patients with acute cerebral infarction. *J Clin Neurol*. 2011;7(4):197-202, <https://doi.org/10.3988/jcn.2011.7.4.197>.
 26. Wang J, Ning R, Wang Y. Plasma D-dimer level, the promising prognostic biomarker for the acute cerebral infarction patients. *J Stroke Cerebrovasc Dis*. 2016;25(8):2011-5, <https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.031>.
 27. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identification of blood biomarker for acute stroke in humans: a comprehensive systematic review. *Br J Clin Pharmacol*. 2012;74(2):230-240, <https://doi.org/10.1111/j.1365-2125.2012.04212.x>.
 28. Matsumoto M, Sakaguchi M, Okazaki S, Furukado S, Tagaya M, Etani H, et al. Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with non-valvular arterial fibrillation. *Cerebrovasc Dis*. 2013;35(1):64-72, <https://doi.org/10.1159/000345336>.
 29. Hisamitsu Y, Kudo T, Fudaba H, Sugita K, Fujiki M, Ide S, et al. High D-dimer concentration is a significant independent prognostic factor in patients with acute large vessel occlusion undergoing endovascular thrombectomy. *World Neurosurg*. 2022;160:e487-e493, <https://doi.org/10.1016/j.wneu.2022.01.052>.
 30. Richards AM. N-terminal B-type natriuretic peptide in heart failure. *Heart Fail Clin*. 2018;14(1):27-39, <https://doi.org/10.1016/j.hfc.2017.08.004>.
 31. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. *N Eng J Med*. 1998; 339(5):321-8.
 32. Daniels LB, Maisel AS. Natriuretic peptides. *J Am Coll Cardiol*. 2007;50(25):2357-2368, <https://doi.org/10.1016/j.jacc.2007.09.021>.

33. Yip HK, Sun CK, Chang LT, Chen MC, Liou CW. Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. *Circ J*. 2006;70(4):447-52, <https://doi.org/10.1253/circj.70.447>.
34. Idris I, Hill R, Ross I, Sharma JC. N-terminal pro-brain natriuretic peptide predicts 1-year mortality following acute stroke: possible evidence of occult cardiac dysfunction among patients with acute stroke. *Age Ageing*. 2010;39(6):752-5, <https://doi.org/10.1093/ageing/afq098>.
35. Castelnuovo AD, Veronesi G, Costanzo S, Zeller T, Schnabel RB, de Curtis A, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the risk of stroke. *Stroke*. 2019;50(3):610-617, <https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.023218>
36. Iltumur K, Yavavli A, Apak I, Ariturk Z, Toprak N. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. *Am Heart J*. 2006;151(5):1115-22, <https://doi.org/10.1016/j.ahj.2005.05.022>.
37. Zecca B, Mandelli C, Maino A, Casiraghi C, Bolla G, Consonni D, et al. A bioclinical pattern for the early diagnosis of cardioembolic stroke. *Emerg Med Int*. 2014;2014: 242171, <https://doi.org/10.1155/2014/242171>.
38. Nakamura M, Ishibashi Y, Tanaka F, Omama S, Onoda T, Takahashi T, et al. Ability of B-Type Natriuretic Peptide Testing to Predict cardioembolic stroke in the general population – comparison with c-reactive protein and urinary albumin. *Circ J*. 2018;82(4):1017-1025, <https://doi.org/10.1253/circj.CJ-17-1124>.
39. Garcia-Berrocoso T, Giralt D, Bustamante A, Etgen T, Jensen JK, Sharma JC, et al. B-type natriuretic peptides and mortality after stroke. a systematic review and meta-analysis. *Neurology*. 2013;81(23):1976-85, <https://doi.org/10.1212/01.wnl.0000436937.32410.32>.
40. Kannel WB, Belanger AJ. Epidemiology of heart failure. *Am Heart J*. 1991;121(3 Pt 1):951-7, [https://doi.org/10.1016/0002-8703\(91\)90225-7](https://doi.org/10.1016/0002-8703(91)90225-7).
41. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic gut flora in patients with chronic heart failure. *JACC Heart Fail*. 2016;4(3):220-227, <https://doi.org/10.1016/j.jchf.2015.10.009>.
42. Haeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke. *Stroke*. 2011;42(10):2977-82, <https://doi.org/10.1161/STROKEAHA.111.628479>.
43. Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrez OM, Jenny NS, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. *Stroke*. 2014;45(6):1646-1650, <https://doi.org/10.1161/STROKEAHA.114.004712>.
44. Zhang X, Wang W, Yu Y, Wang Q, Yang Y, Wen D, et al. BNP and NT-proBNP assays for heart-failure diagnosis inpatients with cerebral infarction. *Lab Medicine* 2013;44(1):46-50, <https://doi.org/10.1309/LMPEAZF6UYU8FG4H>.
45. Zaidat OO, Castonguay A, Linfante I, Gupta R, Martin CO, Holloway WE, et al. First pass effect:

A new measure for stroke thrombectomy devices. *Stroke*. 2018;49(3):660-666, <https://doi.org/10.1161/STROKEAHA.117.020315>.

46. Meretoja A, Keshtkaran M, Tatlisumal T, Donnan GA, Churilov L. Endovascular therapy for ischemic stroke: save a minute-save a week. *Neurology*. 2017;88(22):2123-2127, <https://doi.org/10.1212/WNL.0000000000003981>.
47. Hassan AE, Shariff U, Saver J, Goyal M, Liebeskind D, Jahan R, et al. Impact of procedural time on clinical and angiographic outcomes in patients with acute ischemic stroke receiving endovascular treatment. *J NeuroInterv Surg*. 2019;11(10):984-988, <http://dx.doi.org/10.1136/neurintsurg-2018-014576>.

Figure Legends

Table 1. Patients' characteristics.

Table 2. Occlusion site.

Table 3. Prognostic factor analysis.

Table 4. Binomial logistic regression model analysis for prognostic factor.

	Favourable clinical outcome 28 cases	Unfavourable clinical outcome 31 cases
Hypertension	14 (50%)	25 (80.65%)
Diabetes	4 (14.29%)	8 (25.81%)
Hyperlipidemia	5 (17.86%)	3 (9.68%)
Atrial fibrillation	24 (85.71%)	19 (61.29%)

t-test and M-W test ($p=0.7802$ and $p=0.7728$)

Table 1.
Patients' characteristics

	Favourable clinical outcome 28 cases	Unfavourable clinical outcome 31 cases
Cervical ICA	0	4
Intracranial ICA	1	2
Teriminal ICA	6	7
M1 proximal	6	3
M1 distal	8	10
M2/M3	7	4
Tandem	0	1

t-test and M-W test ($p=0.8129$ and $p=0.7481$)

Table 2.

Occlusion site

ICA: internal carotid artery, M1:middle cerebral artery horizontal segment, M2/M3: middle cerebral artery insular segment/ opercular segment, tandem: sub-occlusion or stenosis of extracranial internal carotid artery, together with simultaneous intracranial large vessel occlusion.

	Favorable clinical outcome 28cases	Unfavorable clinical outcome 31 cases	t-stats	<i>p</i>	M-W test	<i>p</i>
age, median (IQR) years	84 (82.75-86)	85 (83-90)	-2.1998	0.03189 *	329	0.1107
female	11(39.29%)	16(51.6%)				
CT ASPECTS, median (IQR)	9 (7-9.25)	9 (7-9)	-3.6873	0.0962	502.5	0.2867
MRI DWI-ASPECTS, median (IQR)	7.5 (6-9)	8 (6-8)	1.9157	0.3511	381.5	0.587
NIHSS, median (IQR)	20 (16-24.25)	26 (22.5-30)	-3.6873	0.00051 *	213	0.0008 *
intravenous thrombolysis	18 (64.29%)	18 (58.06%)				
HbA1c (median, IQR) (%)	5.9(2.2-6)	6(5.625-6.475)	-1.180004	0.2431	326.5	0.211
D-dimer (median, IQR) ($\mu\text{g/ml}$)	1.25(0.875-1.8)	2(1.2-4.05)	-0.70065	1.4864	255	0.01037 *
NT-proBNP (median, IQR) (pg/ml)	636.65(314.2-913)	1195.5(746.6-1814)	-1.6016	0.1164	169	0.04028 *
TICI2b <	26 (92.86%)	18 (58.06%)	3.28524	0.00175 *	585	0.002457 *
number of passes, median (IQR)	1 (1-2)	2 (1-2)	2.34518	0.02252 *	562	0.024427 *
groin to recanalization time, median (IQR) (min)	41(21.5-57,25)	53(36-72)	-1.28237	0.20491	307	0.05475
arrival to recanalization time, median (IQR) (min)	145(110.75-178.25)	148(117-177)	0.816	0.4178	-0.251	0.8064
onset to arrival time, median (IQR) (min)	52(38.75-165.75)	57(39.5-157)	1.3385	0.186023	441	0.9214

Table 3.

Prognosis factor analysis

CT ASPECTS: Alberta Stroke Early CT score, MRI DWI-ASPECTS: diffusion weighted imaging ASPECTS, NIHSS: National Institutes of Health Stroke Scale, HbA1c:

Glycated hemoglobin, NT-proBNP: N-Terminal Pro-Brain Natriuretic Peptide, mTICI: modified Thrombolysis in Cerebral Infarction, t-test: Student's t-test, M-W test: Mann-

Whitney U test, *: statistically significant.

	B	Standard Error	Wald	<i>p</i>	Exp(B)
Age	-0.164	0.125	1.712	0.191	0.849
NIHSS score on admission	-0.183	0.076	5.749	0.017 *	0.833
NT-proBNP	-0.001	0,000	1.678	0.195	0.999
D-dimer	-0.046	0.99	0.214	0.644	1.047
Number of passes	-0.541	0.578	0.876	0.349	0.582
mTICI $\geq 2b$	2.694	1.377	3.825	0.050	14.788
Constant	16.626	11.065	2.258	0.133	16609785.569

Table 4.

Binomial logistic regression model analysis for prognostic factor:

NIHSS: National Institutes of Health Stroke Scale, NT-proBNP: N-Terminal Pro-Brain Natriuretic Peptide, mTICI: modified Thrombolysis in Cerebral Infarction, *: statistically significant.